title: Antiarrhythmic effects and ionic mechanisms of allicin on myocardial injury of diabetic rats induced by streptozotocin.
abstract: The aim of this study was to evaluate the antiarrhythmic effect of allicin (AL) on streptozotocin (STZ)-induced diabetic rats and explore the possible mechanisms. Hyperglycemia was induced in rats by single intraperitoneal injection of STZ (40 mg/kg). Three days after STZ treatment, the hyperglycemic rats (plasma glucose levels≥16.7 mM) were administered with AL (4, 8, and 16 mg/kg) by intraperitoneal injection daily for 28 days. The fasting blood glucose levels were measured on every seventh day during the 28 days of treatment. The body weight and blood glucose levels were detected after 28 days. Antiarrhythmic effect of AL was observed in the diabetic rats induced by BaCl2. To determine the ionic mechanism in rat ventricular myocytes of AL, action potential duration (APD), L-type calcium current (ICa-L), and inward rectifier potassium current (IK1) were recorded by the whole cell-patch clamp technique. The expressions of L-type calcium channel protein α1C mRNA and cell potassium channels protein Kir2.1 mRNA were studied by RT-PCR. AL normalized the RR interval and QT interval in diabetic rats. AL obviously delayed the onset of ventricular arrhythmia and reduced the score of arrhythmia induced by BaCl2. Electrophysiological experiment revealed that AL could shorten APD through inhibition of ICa-L and enhancement of IK1. RT-PCR analysis indicated that long-term treatment with AL could decrease the expression of α1C mRNA and increase the expression of Kir2.1 mRNA. AL has antiarrhythmic effect in STZ-induced diabetic rats. It is tempting for the application of AL to be a useful therapeutic approach in diabetes with ventricular arrhythmia.
authors.affiliation: Department of Pharmacology, Harbin Medical University-Daqing, Daqing, Heilongjiang, 163319, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
authors.forename: Ye
authors.initials: Y
authors.lastname: Wang
authors.forename: Yong-Gang
authors.initials: YG
authors.lastname: Cao
authors.forename: Han-Ping
authors.initials: HP
authors.lastname: Qi
authors.forename: Lei
authors.initials: L
authors.lastname: Li
authors.forename: Bing
authors.initials: B
authors.lastname: Bai
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.forename: Hong-Li
authors.initials: HL
authors.lastname: Sun
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D017609:Barium Compounds; D001786:Blood Glucose / Q000032:analysis; D020746:Calcium Channels, L-Type / Q000235:genetics; D002712:Chlorides; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D004220:Disulfides; D006321:Heart / Q000503:physiopathology*; D008297:Male; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000502:physiology; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013441:Sulfinic Acids / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000889:Anti-Arrhythmia Agents; D017609:Barium Compounds; D001786:Blood Glucose; D020746:Calcium Channels, L-Type; D002712:Chlorides; D004220:Disulfides; C575188:KCNJ2 protein, rat; C419385:L-type calcium channel alpha(1C); D024661:Potassium Channels, Inwardly Rectifying; D012333:RNA, Messenger; D013441:Sulfinic Acids; C024986:barium chloride; C006452:allicin